SMH
TEVA icon

Sanders Morris Harris’s Teva Pharmaceuticals TEVA Stock Holding History

Sanders Morris Harris’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-13,924
Closed -$76K – 291
2019
Q2 		$76K Buy
+13,924
New +$168K 0.02% 263

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return

Sanders Morris Harris's TEVA Position: Q3 2019 in Review

Sanders Morris Harris sold out of Teva Pharmaceuticals (TEVA) in Q3 2019, closing a stake of 13,924 shares — an estimated $76K sold.

Sanders Morris Harris first reported a position in TEVA in Q2 2019 and held it in 1 quarter. The position peaked at $76K in Q2 2019. 427 funds tracked by Wall St. Rank hold TEVA as of Q3 2019.

  • Sanders Morris Harris reported no remaining Teva Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Sanders Morris Harris sold 13,924 Teva Pharmaceuticals shares in Q3 2019, an estimated $76K.
  • Sanders Morris Harris first reported a position in Teva Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Sanders Morris Harris's Teva Pharmaceuticals position peaked at $76K in Q2 2019.
  • 427 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2019.

Based on Sanders Morris Harris's 13F filing for Q3 2019, filed 14 Nov 2019.